← Leaderboards
Daniel Hal Solomon
Brigham And Women'S Hospital
$26,002,677
Attributed
$35,097,004
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,072,043 · 21
By mechanism
U01$14,446,944 · 2
P30$10,658,933 · 4
R01$9,710,819 · 5
P60$3,625,888 · 2
K24$1,480,175 · 1
R21$1,203,455 · 3
Top collaborators
- Joan Marie Bathon8 shared
- Michael J Barry5 shared
- Hyon K Choi5 shared
- Bing Lu1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Seoyoung Catherine Kim$5,029,016
- Yvonne Claire Lee$9,491,780
- Krista F Huybrechts$10,039,261
- Niteesh K Choudhry$10,267,534
- Elizabeth W Karlson$93,612,751
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsClinical ResearchBasePharmaceutical PreparationsRheumatoid ArthritisCohortRheumatismResearch PersonnelRheumatologyFundingRheumatologistResourcesHospitalsAdultCommunitiesCostMentorsFacultyDesignInflammatoryEnrollmentTrainingCaringEvent
Grant awards (80)
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$1,812,686
U01 · FY2025 · AR
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$801,700
P30 · FY2025 · AR · contact PI
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms$603,179
R01 · FY2025 · HL · contact PI
Administrative Core$257,278
P30 · FY2025 · AR · contact PI
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$1,937,050
U01 · FY2024 · AR
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$891,115
P30 · FY2024 · AR · contact PI
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms$774,845
R01 · FY2024 · HL · contact PI
Administrative Core$310,931
P30 · FY2024 · AR · contact PI
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$2,046,055
U01 · FY2023 · AR
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$891,115
P30 · FY2023 · AR · contact PI
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms$746,264
R01 · FY2023 · HL · contact PI
Administrative Core$301,623
P30 · FY2023 · AR · contact PI
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$910,868
P30 · FY2022 · AR · contact PI
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms$683,150
R01 · FY2022 · HL · contact PI
Administrative Core$276,920
P30 · FY2022 · AR · contact PI
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$888,722
P30 · FY2021 · AR · contact PI
Treatments Against RA and Effect on FDG PET CT: The TARGET TRIAL$566,969
U01 · FY2021 · AR · contact PI
Dietary Quality, Body Adiposity, and Risk of Rheumatoid Arthritis in Women$480,060
R01 · FY2021 · AR · contact PI
Administrative Core$308,371
P30 · FY2021 · AR · contact PI
Planning for a Trial of Comparative Effectiveness of Gout Management Strategies$217,868
R34 · FY2021 · AR
Treatments Against RA and Effect on FDG PET CT: The TARGET TRIAL$1,594,208
U01 · FY2020 · AR · contact PI
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$893,894
P30 · FY2020 · AR · contact PI
Administrative Core$312,729
P30 · FY2020 · AR · contact PI
Planning for a Trial of Comparative Effectiveness of Gout Management Strategies$239,567
R34 · FY2020 · AR
Treatments Against RA and Effect on FDG PET CT:The TARGET Trial$180,878
U01 · FY2020 · AR · contact PI
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$894,906
P30 · FY2019 · AR · contact PI
Administrative Core$323,998
P30 · FY2019 · AR · contact PI
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$895,176
P30 · FY2018 · AR · contact PI
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study$838,133
R01 · FY2018 · HL · contact PI
Administrative Core$316,211
P30 · FY2018 · AR · contact PI
Treatments Against RA and Effect on FDG PET CT: The TARGET TRIAL$2,646,510
U01 · FY2017 · AR · contact PI
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics$907,543
P30 · FY2017 · AR · contact PI
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study$840,301
R01 · FY2017 · HL · contact PI
Administrative Core$275,833
P30 · FY2017 · AR · contact PI
Patient Centered Outcomes Research in Rheumatology$145,700
K24 · FY2017 · AR · contact PI
Treatments Against RA and Effect on FDG PET CT: The TARGET TRIAL$2,699,027
U01 · FY2016 · AR · contact PI
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study$806,193
R01 · FY2016 · HL · contact PI
Rheumatic expertise expanded access to improve community health REACH-RA$349,575
P60 · FY2016 · AR · contact PI
Patient Centered Outcomes Research in Rheumatology$145,700
K24 · FY2016 · AR · contact PI
Treatments Against RA and Effect on FDG PET CT: The TARGET TRIAL$963,561
U01 · FY2015 · AR · contact PI
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study$682,979
R01 · FY2015 · HL · contact PI
Rheumatic expertise expanded access to improve community health REACH-RA$343,591
P60 · FY2015 · AR · contact PI
Patient Centered Outcomes Research in Rheumatology$145,700
K24 · FY2015 · AR · contact PI
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study$693,860
R01 · FY2014 · HL · contact PI
Rheumatic expertise expanded access to improve community health REACH-RA$400,719
P60 · FY2014 · AR · contact PI
Treat to Target to Reduce Atherosclerosis in Rheumatoid Arthritis$350,488
U34 · FY2014 · AR · contact PI
Patient Centered Outcomes Research in Rheumatology$145,700
K24 · FY2014 · AR · contact PI
Rheumatic expertise expanded access to improve community health REACH-RA$388,885
P60 · FY2013 · AR · contact PI
Treat to Target to Reduce Atherosclerosis in Rheumatoid Arthritis$369,319
U34 · FY2013 · AR · contact PI
Patient Centered Outcomes Research in Rheumatology$145,700
K24 · FY2013 · AR · contact PI
Modifiable Disparities in Treatment for Rheumatoid Arthritis$583,444
R01 · FY2012 · AR · contact PI
Rheumatic expertise expanded access to improve community health REACH-RA$375,902
P60 · FY2012 · AR · contact PI
Estimating and Communicating Risk about Biologic DMARDs for Rheumatoid Arthritis$150,335
K24 · FY2012 · AR · contact PI
Modifiable Disparities in Treatment for Rheumatoid Arthritis$584,790
R01 · FY2011 · AR · contact PI
Improving Medication Adherence for Osteoporosis:Community Based Randomized Con$321,589
P60 · FY2011 · AR · contact PI
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis$205,685
R21 · FY2011 · AR · contact PI
Estimating and Communicating Risk about Biologic DMARDs for Rheumatoid Arthritis$150,335
K24 · FY2011 · AR · contact PI
Modifiable Disparities in Treatment for Rheumatoid Arthritis$384,185
R01 · FY2010 · AR · contact PI
Improving Medication Adherence for Osteoporosis:Community Based Randomized Con$375,204
P60 · FY2010 · AR · contact PI
Osteonecrosis of the Jaw in Non-Cancer Patients Using Bisphosphonates$222,500
R21 · FY2010 · DE · contact PI
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis$173,597
R21 · FY2010 · AR · contact PI
Estimating and Communicating Risk about Biologic DMARDs for Rheumatoid Arthritis$150,335
K24 · FY2010 · AR · contact PI
Improving Medication Adherence for Osteoporosis:Community Based Randomized Con$374,994
P60 · FY2009 · AR · contact PI
Modifiable Disparities in Treatment for Rheumatoid Arthritis$362,980
R01 · FY2009 · AR · contact PI
Osteonecrosis of the Jaw in Non-Cancer Patients Using Bisphosphonates$266,750
R21 · FY2009 · DE · contact PI
Estimating and Communicating Risk about Biologic DMARDs for Rheumatoid Arthritis$150,335
K24 · FY2009 · AR · contact PI
Improving Medication Adherence for Osteoporosis:Community Based Randomized Con$394,840
P60 · FY2008 · AR · contact PI
Estimating and Communicating Risk about Biologic DMARDs for Rheumatoid Arthritis$150,335
K24 · FY2008 · AR · contact PI
Improving Medication Adherence for Osteoporosis:Community Based Randomized Con$300,589
P60 · FY2007 · AR · contact PI
Randomized Controlled Testing of Osteoporosis Education$133,769
K23 · FY2006 · AR · contact PI
Osteoporosis in Women with Rheumatoid Arthritis$119,859
R21 · FY2006 · AG · contact PI
Osteoporosis in Women with Rheumatoid Arthritis$215,064
R21 · FY2005 · AG
Randomized Controlled Testing of Osteoporosis Education$133,779
K23 · FY2005 · AR
Pain Medication Use &Risk Factors for Opioid Dependence$216,250
R01 · FY2004 · DA
Randomized Controlled Testing of Osteoporosis Education$133,699
K23 · FY2004 · AR
Pain Medication Use &Risk Factors for Opioid Dependence$214,060
R01 · FY2003 · DA
Randomized Controlled Testing of Osteoporosis Education$133,631
K23 · FY2003 · AR
Pain Medication Use &Risk Factors for Opioid Dependence$216,146
R01 · FY2002 · DA
Randomized Controlled Testing of Osteoporosis Education$133,709
K23 · FY2002 · AR
Why is Cardiac Risk Increased in Rheumatiod Arthritis$100,000
R55 · FY2002 · AR